233 related articles for article (PubMed ID: 37451271)
1. A distinct stimulatory cDC1 subpopulation amplifies CD8
Meiser P; Knolle MA; Hirschberger A; de Almeida GP; Bayerl F; Lacher S; Pedde AM; Flommersfeld S; Hönninger J; Stark L; Stögbauer F; Anton M; Wirth M; Wohlleber D; Steiger K; Buchholz VR; Wollenberg B; Zielinski CE; Braren R; Rueckert D; Knolle PA; Kaissis G; Böttcher JP
Cancer Cell; 2023 Aug; 41(8):1498-1515.e10. PubMed ID: 37451271
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
Bayerl F; Meiser P; Donakonda S; Hirschberger A; Lacher SB; Pedde AM; Hermann CD; Elewaut A; Knolle M; Ramsauer L; Rudolph TJ; Grassmann S; Öllinger R; Kirchhammer N; Trefny M; Anton M; Wohlleber D; Höchst B; Zaremba A; Krüger A; Rad R; Obenauf AC; Schadendorf D; Zippelius A; Buchholz VR; Schraml BU; Böttcher JP
Immunity; 2023 Jun; 56(6):1341-1358.e11. PubMed ID: 37315536
[TBL] [Abstract][Full Text] [Related]
3. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
4. Conventional type 1 dendritic cells (cDC1) in cancer immunity.
Liu P; Zhao L; Kroemer G; Kepp O
Biol Direct; 2023 Nov; 18(1):71. PubMed ID: 37907944
[TBL] [Abstract][Full Text] [Related]
5. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract][Full Text] [Related]
7. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
8. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.
Teijeira A; Garasa S; Luri-Rey C; de Andrea C; Gato M; Molina C; Kaisho T; Cirella A; Azpilikueta A; Wculek SK; Egea J; Olivera I; Rodriguez I; Rouzaut A; Verkhusha V; Valencia K; Sancho D; Berraondo P; Melero I
Cancer Res; 2022 Dec; 82(23):4373-4385. PubMed ID: 36130020
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
10. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
11. The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain.
Bowman-Kirigin JA; Desai R; Saunders BT; Wang AZ; Schaettler MO; Liu CJ; Livingstone AJ; Kobayashi DK; Durai V; Kretzer NM; Zipfel GJ; Leuthardt EC; Osbun JW; Chicoine MR; Kim AH; Murphy KM; Johanns TM; Zinselmeyer BH; Dunn GP
Cancer Immunol Res; 2023 Jan; 11(1):20-37. PubMed ID: 36409838
[TBL] [Abstract][Full Text] [Related]
12. CD4
Lei X; Khatri I; de Wit T; de Rink I; Nieuwland M; Kerkhoven R; van Eenennaam H; Sun C; Garg AD; Borst J; Xiao Y
Nat Commun; 2023 Jan; 14(1):217. PubMed ID: 36639382
[TBL] [Abstract][Full Text] [Related]
13. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.
Böttcher JP; Bonavita E; Chakravarty P; Blees H; Cabeza-Cabrerizo M; Sammicheli S; Rogers NC; Sahai E; Zelenay S; Reis e Sousa C
Cell; 2018 Feb; 172(5):1022-1037.e14. PubMed ID: 29429633
[TBL] [Abstract][Full Text] [Related]
14. cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
Ferris ST; Ohara RA; Ou F; Wu R; Huang X; Kim S; Chen J; Liu TT; Schreiber RD; Murphy TL; Murphy KM
Cancer Immunol Res; 2022 Aug; 10(8):920-931. PubMed ID: 35648641
[TBL] [Abstract][Full Text] [Related]
15. Platelets interact with CD169
Grabowska J; Léopold V; Olesek K; Nijen Twilhaar MK; Affandi AJ; Brouwer MC; Jongerius I; Verschoor A; van Kooten C; van Kooyk Y; Storm G; van 't Veer C; den Haan JMM
Front Immunol; 2023; 14():1290272. PubMed ID: 38054006
[TBL] [Abstract][Full Text] [Related]
16. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4
Mattiuz R; Brousse C; Ambrosini M; Cancel JC; Bessou G; Mussard J; Sanlaville A; Caux C; Bendriss-Vermare N; Valladeau-Guilemond J; Dalod M; Crozat K
Clin Transl Immunology; 2021; 10(7):e1305. PubMed ID: 34277006
[TBL] [Abstract][Full Text] [Related]
17. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.
Lau CM; Tiniakou I; Perez OA; Kirkling ME; Yap GS; Hock H; Reizis B
J Exp Med; 2018 Sep; 215(9):2265-2278. PubMed ID: 30087163
[TBL] [Abstract][Full Text] [Related]
18. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
19. DNGR-1-mediated cross-presentation of dead cell-associated antigens.
Henry CM; Castellanos CA; Reis e Sousa C
Semin Immunol; 2023 Mar; 66():101726. PubMed ID: 36758378
[TBL] [Abstract][Full Text] [Related]
20. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity.
Böttcher JP; Reis e Sousa C
Trends Cancer; 2018 Nov; 4(11):784-792. PubMed ID: 30352680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
